MC4R (Melanocortin receptor 4) variants and mutations
MC4R (also known as Melanocortin receptor 4) is a human protein-coding gene encoding a melanocortin receptor 4 protein. Its melanocortin signaling in hypothalamic circuits suppresses appetite and helps regulate energy expenditure and body weight. Loss-of-function variants are the most common known cause of monogenic obesity and typically produce early hyperphagia. This analysis covers 850 MC4R variants and mutations. Of these, 89% have computational variant effect predictions. Disease context includes obesity disorder, Obesity, and Abnormality of the skeletal system. Example MC4R variants include V2A, N3K, and N3S.
Variant analysis overview
- Gene: MC4R
- Protein: Melanocortin receptor 4
- UniProt accession: P32245
- Organism: Homo sapiens
- Variants analyzed: 850
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 524 unspecified-consequence records; 150 synonymous variants; 132 missense variants; 29 frameshift variants; 6 in-frame deletions; 4 stop-gained variants; 5 substitution
- Prediction scores: 756 variants have prediction scores (89% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: obesity disorder, Obesity, Abnormality of the skeletal system, obesity due to melanocortin 4 receptor deficiency, type 2 diabetes mellitus, sexual dysfunction, Bardet-Biedl syndrome, diabetes mellitus, metabolic syndrome, overnutrition, dentures, inherited obesity.
Protein structure and variant hotspots
- Protein features: 7 transmembrane segments; 3 binding sites; 3 post-translational modification sites.
- Structural context: 404 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable MC4R variants
Examples include V2A, N3K, N3S, S4A, S4F, S4Y, S4S, S4C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- V2A (p.Val2Ala), gnomAD 18-60372345-A-G, REVEL 0.10, MetaLR 0.08
- N3K (p.Asn3Lys), NCI-TCGA Cosmic COSV5535, Variant assessed as somatic; moderate impact.
- N3S (p.Asn3Ser), gnomAD 18-60372342-T-C, REVEL 0.06, MetaLR 0.07
- S4A (p.Ser4Ala), TOPMed rs1915368592
- S4F (p.Ser4Phe), rs146099234, ClinGen CA8981009, ClinVar RCV003402957, ClinVar RCV006444088, REVEL 0.04, MetaLR 0.09, Uncertain significance, not provided; Early onset severe obesity
- S4Y (p.Ser4Tyr), ESP rs146099234, ExAC rs146099234, TOPMed rs146099234, gnomAD rs146099234, MetaLR 0.09, MetaSVM -1.01, Uncertain significance
- S4S (p.Ser4Ser), rs757561015, gnomAD 18-60372338-G-A, CADD 6.02
- S4C (p.Ser4Cys), gnomAD 18-60372339-G-C, REVEL 0.05, MetaLR 0.10
- T5I (p.Thr5Ile), rs752432398, ExAC rs752432398, TOPMed rs752432398, gnomAD rs752432398, REVEL 0.14, MetaLR 0.08, Uncertain significance
- T5N (p.Thr5Asn), rs752432398, ClinGen CA8981007, ClinVar RCV001174414, ClinVar RCV002483938, REVEL 0.10, MetaLR 0.09, Uncertain significance
- T5S (p.Thr5Ser), Ensembl rs1009938037
- T5T (p.Thr5Thr), rs199862517, gnomAD 18-60372335-G-A, CADD 2.22
- H6Y (p.His6Tyr), Ensembl rs1205226959, REVEL 0.08, MetaLR 0.11
- H6H (p.His6His), rs1915367991, gnomAD 18-60372332-G-A, CADD 1.89
- R7C (p.Arg7Cys), ExAC rs753796542, TOPMed rs753796542, gnomAD rs753796542, REVEL 0.12, MetaLR 0.14
- R7H (p.Arg7His), rs142837166, ClinGen CA8981003, NCI-TCGA Cosmic COSV1002, ClinVar RCV003420742, REVEL 0.18, MetaLR 0.09, Conflicting interpretations, not provided; BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20; Early onset severe ob
- R7L (p.Arg7Leu), NCI-TCGA Cosmic COSV1002, REVEL 0.16, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- R7S (p.Arg7Ser), ExAC rs753796542, TOPMed rs753796542, gnomAD rs753796542, REVEL 0.13, MetaLR 0.13
- R7R (p.Arg7Arg), rs760074702, gnomAD 18-60372329-A-G, CADD 2.38
- G8A (p.Gly8Ala), TOPMed rs1406378947, MetaLR 0.08, MetaSVM -1.06
- G8G (p.Gly8Gly), rs148256915, gnomAD 18-60372326-C-T, CADD 4.62
- G8E (p.Gly8Glu), gnomAD 18-60372327-C-T, REVEL 0.16, MetaLR 0.08
- M9L (p.Met9Leu), TOPMed rs1915367482
- M9T (p.Met9Thr), gnomAD 18-60372324-A-G, REVEL 0.06, MetaLR 0.05
- M9V (p.Met9Val), gnomAD 18-60372325-T-C, REVEL 0.10, MetaLR 0.07
- H10H (p.His10His), rs143128989, gnomAD 18-60372320-G-A, CADD 7.50
- T11A (p.Thr11Ala), rs372794914, ClinGen CA8981000, ClinVar RCV001174413, ClinVar RCV002483937, REVEL 0.03, MetaLR 0.04, Benign
- T11I (p.Thr11Ile), ExAC rs761529157, TOPMed rs761529157, gnomAD rs761529157, REVEL 0.06, MetaLR 0.04
- T11T (p.Thr11Thr), gnomAD 18-60372317-A-G, CADD 5.76
- S12F (p.Ser12Phe), NCI-TCGA Cosmic COSV1002, Variant assessed as somatic; moderate impact.
- S12P (p.Ser12Pro), gnomAD rs1207320659, REVEL 0.06, MetaLR 0.03
- S12Y (p.Ser12Tyr), NCI-TCGA Cosmic COSV1002, REVEL 0.07, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- S12S (p.Ser12Ser), gnomAD 18-60372314-A-G, CADD 9.20
- L13L (p.Leu13Leu), gnomAD 18-60372311-C-T, CADD 7.69
- L13P (p.Leu13Pro), gnomAD 18-60372312-A-G, REVEL 0.11, MetaLR 0.12
- H14P (p.His14Pro), NCI-TCGA Cosmic COSV1002, Variant assessed as somatic; moderate impact.
- H14Q (p.His14Gln), ExAC rs769164724, gnomAD rs769164724
- L15F (p.Leu15Phe), Ensembl rs765520842, REVEL 0.02, MetaLR 0.02
- W16L (p.Trp16Leu), gnomAD 18-60372303-C-A, REVEL 0.14, MetaLR 0.06
- W16R (p.Trp16Arg), gnomAD 18-60372304-A-G, REVEL 0.13, MetaLR 0.07
- N17E (p.Asn17Glu), rs1226732666, gnomAD 18-60372301-T-TC, CADD 28.00
- R18C (p.Arg18Cys), rs749768113, NCI-TCGA Cosmic COSV5535, ExAC rs749768113, gnomAD rs749768113, REVEL 0.12, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- R18H (p.Arg18His), rs780671601, ExAC rs780671601, TOPMed rs780671601, gnomAD rs780671601, REVEL 0.23, MetaLR 0.02, Uncertain significance
- R18L (p.Arg18Leu), rs780671601, ClinGen CA8980994, ClinVar RCV002015992, ClinVar RCV002507777, REVEL 0.31, MetaLR 0.02, Uncertain significance, not provided; BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20
- R18S (p.Arg18Ser), ExAC rs749768113, gnomAD rs749768113, REVEL 0.13, MetaLR 0.04
- R18R (p.Arg18Arg), gnomAD 18-60372296-G-T, CADD 10.80
- S19G (p.Ser19Gly), UniProt VAR 091157, REVEL 0.07, MetaLR 0.12, Uncertain significance
- S19A (p.Ser19Ala), rs1313804073, gnomAD 18-60372294-CT-C, CADD 28.40
- S20G (p.Ser20Gly), NCI-TCGA Cosmic COSV1002, MetaLR 0.05, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- Y21* (p.Tyr21Ter), rs770293321, ClinGen CA8980992, ClinVar RCV000582390, ClinVar RCV004017689, CADD 20.10, Likely pathogenic
- L23R (p.Leu23Arg), gnomAD 18-60372281-CA-C, CADD 22.30
- L23L (p.Leu23Leu), rs1401007330, gnomAD 18-60372281-C-T, CADD 8.45
- H24N (p.His24Asn), TOPMed rs905335629, gnomAD rs905335629, REVEL 0.08, MetaLR 0.08, Uncertain significance, MC4R-related disorder
- H24R (p.His24Arg), Ensembl rs1486783810, MetaLR 0.08, MetaSVM -1.01
- S25R (p.Ser25Arg), ExAC rs770469626, gnomAD rs770469626, REVEL 0.06, MetaLR 0.10
- S25S (p.Ser25Ser), gnomAD 18-60372275-G-A, CADD 11.00
- S25N (p.Ser25Asn), gnomAD 18-60372276-C-T, REVEL 0.07, MetaLR 0.12
- S25T (p.Ser25Thr), gnomAD 18-60372276-C-G, REVEL 0.06, MetaLR 0.08
- N26D (p.Asn26Asp), TOPMed rs1375424360, gnomAD rs1375424360, REVEL 0.02, MetaLR 0.06
- N26K (p.Asn26Lys), gnomAD rs1371133103, REVEL 0.02, MetaLR 0.05
- N26N (p.Asn26Asn), gnomAD 18-60372272-A-G, CADD 1.50
- A27D (p.Ala27Asp), TOPMed rs1167880919, gnomAD rs1167880919, REVEL 0.04, MetaLR 0.07
- A27T (p.Ala27Thr), ExAC rs745919097, REVEL 0.03, MetaLR 0.07
- A27V (p.Ala27Val), NCI-TCGA TCGA novel, TOPMed rs1167880919, gnomAD rs1167880919, REVEL 0.03, MetaLR 0.05, Uncertain significance, Early onset severe obesity
- S28I (p.Ser28Ile), TOPMed rs1230316014, gnomAD rs1230316014, REVEL 0.08, MetaLR 0.08
- S28R (p.Ser28Arg), gnomAD rs1427649826, REVEL 0.08, MetaLR 0.09, Uncertain significance, not specified
- S30F (p.Ser30Phe), rs13447323, ClinGen CA8980989, ClinVar RCV003417105, ClinVar RCV006616892, REVEL 0.14, MetaLR 0.07, Uncertain significance, not provided
- S30Y (p.Ser30Tyr), NCI-TCGA Cosmic COSV5535, MetaLR 0.08, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- S30S (p.Ser30Ser), rs775359839, gnomAD 18-60372260-G-A, CADD 9.08
- L31F (p.Leu31Phe), 1000Genomes rs545718295, ExAC rs545718295, REVEL 0.07, MetaLR 0.08
- L31L (p.Leu31Leu), gnomAD 18-60372257-A-G, CADD 4.41
- G32E (p.Gly32Glu), ExAC rs778632018, TOPMed rs778632018, gnomAD rs778632018, REVEL 0.04, MetaLR 0.06
- G32R (p.Gly32Arg), gnomAD 18-60372256-C-G, REVEL 0.13, MetaLR 0.09
- K33Q (p.Lys33Gln), gnomAD rs1184485471, REVEL 0.05, MetaLR 0.05
- K33R (p.Lys33Arg), gnomAD 18-60372252-T-C, REVEL 0.04, MetaLR 0.07
- G34A (p.Gly34Ala), ExAC rs754799513, TOPMed rs754799513, gnomAD rs754799513, UniProt VAR 091159, REVEL 0.04, MetaLR 0.06, Uncertain significance
- G34C (p.Gly34Cys), gnomAD rs1483418974, REVEL 0.14, MetaLR 0.08
- G34D (p.Gly34Asp), ExAC rs754799513, TOPMed rs754799513, gnomAD rs754799513
- G34R (p.Gly34Arg), gnomAD rs1483418974, REVEL 0.20, MetaLR 0.06
- G34V (p.Gly34Val), ExAC rs754799513, TOPMed rs754799513, gnomAD rs754799513, REVEL 0.07, MetaLR 0.08
- G34G (p.Gly34Gly), rs753675859, gnomAD 18-60372248-G-C, CADD 9.26
- Y35* (p.Tyr35Ter), rs13447324, ClinGen CA214751, ClinVar RCV000015394, ClinVar RCV000202583, CADD 35.00, Pathogenic
- Y35C (p.Tyr35Cys), 1000Genomes rs193213449, ExAC rs193213449, TOPMed rs193213449, gnomAD rs193213449, REVEL 0.09, MetaLR 0.08
- Y35H (p.Tyr35His), TOPMed rs1181535625, gnomAD rs1181535625, REVEL 0.01, MetaLR 0.03, Uncertain significance, MC4R-related disorder
- S36F (p.Ser36Phe), ExAC rs749834711, TOPMed rs749834711, gnomAD rs749834711, REVEL 0.10, MetaLR 0.09
- S36T (p.Ser36Thr), TOPMed rs954123325, gnomAD rs954123325, REVEL 0.04, MetaLR 0.07, Uncertain significance, MC4R-related disorder
- S36Y (p.Ser36Tyr), UniProt VAR 038633, Uncertain significance
- S36P (p.Ser36Pro), gnomAD 18-60372244-A-G, REVEL 0.05, MetaLR 0.08
- D37G (p.Asp37Gly), ESP rs13447325, ExAC rs13447325, TOPMed rs13447325, gnomAD rs13447325, REVEL 0.07, MetaLR 0.03, Pathogenic
- D37N (p.Asp37Asn), NCI-TCGA Cosmic COSV5535, Variant assessed as somatic; moderate impact.
- D37V (p.Asp37Val), rs13447325, ClinGen CA213428, ClinVar RCV000015395, ClinVar RCV000435394, REVEL 0.06, MetaLR 0.05, Conflicting interpretations, BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20; not provided; not specified
- D37Y (p.Asp37Tyr), TOPMed rs1915364294
- D37E (p.Asp37Glu), gnomAD 18-60372239-A-T, REVEL 0.07, MetaLR 0.05
- G38R (p.Gly38Arg), ExAC rs761322927, gnomAD rs761322927, REVEL 0.19, MetaLR 0.15
- G39E (p.Gly39Glu), TOPMed rs1322814784, gnomAD rs1322814784, REVEL 0.27, MetaLR 0.21
- G39R (p.Gly39Arg), TOPMed rs1915364068, REVEL 0.27, MetaLR 0.16
- G39G (p.Gly39Gly), gnomAD 18-60372233-C-G, CADD 3.64
- C40* (p.Cys40Ter), TOPMed rs1915363856
- C40R (p.Cys40Arg), TOPMed rs1915363909
- C40Y (p.Cys40Tyr), Ensembl rs2143967443, REVEL 0.29, MetaLR 0.12
- C40W (p.Cys40Trp), gnomAD 18-60372230-G-C, REVEL 0.16, MetaLR 0.14
- Y41Y (p.Tyr41Tyr), rs763385086, gnomAD 18-60372227-G-A, CADD 2.58
- Y41H (p.Tyr41His), gnomAD 18-60372229-A-G, REVEL 0.20, MetaLR 0.11
- E42D (p.Glu42Asp), TOPMed rs1356210856, REVEL 0.17, MetaLR 0.13
- E42K (p.Glu42Lys), rs776051881, NCI-TCGA Cosmic COSV5535, ExAC rs776051881, TOPMed rs776051881, REVEL 0.22, MetaLR 0.17, Uncertain significance, not provided
- E42Q (p.Glu42Gln), ExAC rs776051881, TOPMed rs776051881, gnomAD rs776051881
- E42G (p.Glu42Gly), rs1915363587, gnomAD 18-60372224-CT-C, CADD 28.80
- Q43* (p.Gln43Ter), Ensembl rs1288335099, CADD 38.00
- Q43H (p.Gln43His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q43K (p.Gln43Lys), rs1288335099, ClinGen CA402720476, ClinVar RCV002464551, REVEL 0.37, MetaLR 0.14, Likely pathogenic, Obesity
- Q43Q (p.Gln43Gln), rs770200773, gnomAD 18-60372221-T-C, CADD 9.88
- L44F (p.Leu44Phe), TOPMed rs1915363184
- L44P (p.Leu44Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L44V (p.Leu44Val), gnomAD 18-60372220-G-C, REVEL 0.10, MetaLR 0.05
- F45F (p.Phe45Phe), gnomAD 18-60372215-A-G, CADD 9.23
- V46A (p.Val46Ala), ExAC rs746393702, gnomAD rs746393702
- V46I (p.Val46Ile), gnomAD rs1163674339, REVEL 0.09, MetaLR 0.04
- S47F (p.Ser47Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P48L (p.Pro48Leu), ExAC rs776520178, gnomAD rs776520178, REVEL 0.11, MetaLR 0.09, Uncertain significance, not provided
- P48S (p.Pro48Ser), gnomAD rs1367004987, REVEL 0.20, MetaLR 0.08
- E49A (p.Glu49Ala), gnomAD rs1473006541, REVEL 0.46, MetaLR 0.19
- V50L (p.Val50Leu), gnomAD rs121913557, REVEL 0.16, AlphaMissense 0.37, Pathogenic
- V50M (p.Val50Met), rs121913557, ClinGen CA210713, ClinVar RCV000015396, ClinVar RCV004760334, AlphaMissense 0.37, MetaLR 0.26, Uncertain significance, not provided
- F51L (p.Phe51Leu), ESP rs147000967, TOPMed rs147000967, gnomAD rs147000967, REVEL 0.69, MetaLR 0.20, Likely pathogenic, BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20
- F51C (p.Phe51Cys), gnomAD 18-60372198-A-C, REVEL 0.66, MetaLR 0.15
- V52A (p.Val52Ala), NCI-TCGA TCGA novel, TOPMed rs1453861734, gnomAD rs1453861734, MetaLR 0.08, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- V52E (p.Val52Glu), TOPMed rs1453861734, gnomAD rs1453861734, REVEL 0.39, MetaLR 0.14
- V52V (p.Val52Val), gnomAD 18-60372194-C-T, CADD 9.88
- V52M (p.Val52Met), gnomAD 18-60372196-C-T, REVEL 0.15, MetaLR 0.10
- V52L (p.Val52Leu), gnomAD 18-60372196-C-G, REVEL 0.07, MetaLR 0.03
- T53I (p.Thr53Ile), rs141148170, ESP rs141148170, ExAC rs141148170, gnomAD rs141148170, REVEL 0.06, MetaLR 0.04, Uncertain significance
- L54P (p.Leu54Pro), rs376439188, ClinGen CA8980972, ClinVar RCV000582060, ClinVar RCV005091521, REVEL 0.73, MetaLR 0.16, Uncertain significance
- L54L (p.Leu54Leu), gnomAD 18-60372188-C-G, CADD 9.01
- G55C (p.Gly55Cys), ExAC rs777940806, gnomAD rs777940806, REVEL 0.62, MetaLR 0.15
- G55D (p.Gly55Asp), TOPMed rs1270948834, gnomAD rs1270948834, UniProt VAR 091164, Uncertain significance
- G55S (p.Gly55Ser), ExAC rs777940806, gnomAD rs777940806
- G55V (p.Gly55Val), TOPMed rs1270948834, gnomAD rs1270948834, UniProt VAR 091165, REVEL 0.68, MetaLR 0.15, Uncertain significance
- G55G (p.Gly55Gly), gnomAD 18-60372185-A-G, CADD 3.14
- V56A (p.Val56Ala), Ensembl rs961394506
- V56V (p.Val56Val), rs374441978, gnomAD 18-60372182-G-A, CADD 9.21
- I57L (p.Ile57Leu), ExAC rs749070050, gnomAD rs749070050, REVEL 0.09, MetaLR 0.03
- I57H (p.Ile57His), gnomAD 18-60372181-T-TG, CADD 27.90
- S58C (p.Ser58Cys), rs121913558, ClinGen CA210714, ClinVar RCV000015397, UniProt VAR 038635, REVEL 0.61, MetaLR 0.25, Pathogenic, BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20
- S58A (p.Ser58Ala), rs746241281, gnomAD 18-60372178-TG-T, CADD 12.50
- L59F (p.Leu59Phe), Ensembl rs1915361645
- L59S (p.Leu59Ser), gnomAD rs1373340959, REVEL 0.54, MetaLR 0.06
- L59V (p.Leu59Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L59L (p.Leu59Leu), gnomAD 18-60372173-C-T, CADD 8.31
- L60F (p.Leu60Phe), gnomAD rs1439366696
- L60L (p.Leu60Leu), rs1439366696, gnomAD 18-60372170-C-T, CADD 9.75
- E61D (p.Glu61Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E61G (p.Glu61Gly), UniProt VAR 091166, Uncertain significance
- E61K (p.Glu61Lys), rs370479598, ClinGen CA8980967, ClinVar RCV000501559, ClinVar RCV000518806, REVEL 0.75, MetaLR 0.35, Pathogenic
- E61E (p.Glu61Glu), rs1324120057, gnomAD 18-60372167-C-T, CADD 9.41
- N62S (p.Asn62Ser), rs121913566, ClinGen CA210724, ClinVar RCV000015410, ClinVar RCV004017251, REVEL 0.95, MetaLR 0.96, Likely pathogenic, Obesity due to melanocortin 4 receptor deficiency
- I63F (p.Ile63Phe), ExAC rs750396034, gnomAD rs750396034, REVEL 0.28, MetaLR 0.04
- I63T (p.Ile63Thr), gnomAD 18-60372162-A-G, REVEL 0.28, MetaLR 0.03
- I63L (p.Ile63Leu), gnomAD 18-60372163-T-G, REVEL 0.08, MetaLR 0.01
- L64I (p.Leu64Ile), ExAC rs766896933, TOPMed rs766896933, gnomAD rs766896933, REVEL 0.68, MetaLR 0.62
- L64S (p.Leu64Ser), gnomAD rs1457998784, REVEL 0.87, MetaLR 0.63
- L64F (p.Leu64Phe), gnomAD 18-60372158-T-G, REVEL 0.70, MetaLR 0.44
- V65E (p.Val65Glu), TOPMed rs1915360985, gnomAD rs1915360985, REVEL 0.93, MetaLR 0.86
- V65M (p.Val65Met), TOPMed rs1598932401, REVEL 0.91, MetaLR 0.87
- I66T (p.Ile66Thr), gnomAD 18-60372153-A-G, REVEL 0.82, MetaLR 0.71
- I66V (p.Ile66Val), gnomAD 18-60372154-T-C, REVEL 0.20, MetaLR 0.26
- V67A (p.Val67Ala), gnomAD rs1439634703, REVEL 0.09, MetaLR 0.00
- V67V (p.Val67Val), rs886054076, gnomAD 18-60372149-C-T, CADD 7.14
- V67G (p.Val67Gly), gnomAD 18-60372150-A-C, REVEL 0.26, MetaLR 0.01
- A68S (p.Ala68Ser), gnomAD rs1360504571, REVEL 0.32, MetaLR 0.07
- A68T (p.Ala68Thr), NCI-TCGA Cosmic COSV5535, REVEL 0.42, MetaLR 0.10, Uncertain significance, Early onset severe obesity
- A68V (p.Ala68Val), gnomAD rs1157101126, UniProt VAR 091168, REVEL 0.51, MetaLR 0.11, Uncertain significance, MC4R-related disorder
- A68A (p.Ala68Ala), rs756756728, gnomAD 18-60372146-T-C, CADD 2.22
- I69R (p.Ile69Arg), rs751160202, ClinGen CA209140, ClinVar RCV000194758, ExAC rs751160202, AlphaMissense 0.99, MetaLR 0.13, Pathogenic, Obesity, autosomal dominant
- I69T (p.Ile69Thr), ExAC rs751160202, gnomAD rs751160202, UniProt VAR 091170, REVEL 0.59, AlphaMissense 0.99, Conflicting interpretations, not provided; Early onset severe obesity
- A70D (p.Ala70Asp), UniProt VAR 091171, Uncertain significance, Early onset severe obesity
- A70G (p.Ala70Gly), TOPMed rs1198759731, gnomAD rs1198759731, REVEL 0.14, MetaLR 0.02, Uncertain significance
- A70T (p.Ala70Thr), Ensembl rs2143967279, REVEL 0.16, MetaLR 0.02
- A70V (p.Ala70Val), TOPMed rs1198759731, gnomAD rs1198759731, MetaLR 0.01, MetaSVM -0.88, Uncertain significance, not specified
- A70A (p.Ala70Ala), rs763822900, gnomAD 18-60372140-G-T, CADD 9.83
- K71R (p.Lys71Arg), ExAC rs762757992, gnomAD rs762757992, REVEL 0.11, MetaLR 0.01
Public MC4R analysis runs
- MC4R analysis run — MC4R (850 variants) — completed 2026-08-18